Status:
RECRUITING
Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Gastritis
Eligibility:
All Genders
19-75 years
Brief Summary
This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.
Detailed Description
In this observational study, patient-reported data will be collected using an electronic application (e-PRO). The survey on subjective symptoms will be administered twice-once before and once after th...
Eligibility Criteria
Inclusion
- Adult subjects between the ages of 19 and 75 years at the time of obtaining written informed consent.
- Subjects who are scheduled to receive Fexuclu tablets (fexuprazan) in accordance with the approved indication.
- Subjects who present with at least one subjective symptom requiring medical treatment
- Subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data.
Exclusion
- Individuals who fall under any contraindications for the administration of Fexuclu tablets (fexuprazan) as specified in the approved labeling.
- Individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.
Key Trial Info
Start Date :
June 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 3 2027
Estimated Enrollment :
12000 Patients enrolled
Trial Details
Trial ID
NCT06948487
Start Date
June 17 2025
End Date
June 3 2027
Last Update
July 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Masong Kim Internal Medicine Clinic
Seoul, South Korea